Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
Status:
Completed
Trial end date:
2017-07-06
Target enrollment:
Participant gender:
Summary
DS-5565 (mirogabalin) is being studied as treatment for fibromyalgia (FM) pain. Because it is
excreted through the kidneys, people who have reduced kidney function will not process the
drug as well as with those with normal kidney function, so the dose must be reduced. This
study will test two reduced dose levels for both moderately reduced and severely reduced
kidney function. The study will test the hypothesis that the drug will be safe and
well-tolerated in people who have both fibromyalgia and chronic kidney disease.